EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Phage-antibiotic synergy attenuates Acinetobacter baumannii resistance in refractory pneumonia: a precision therapeutic case

Lei Zhang, Kexin Yan, Pengli Xu, Yanyu Xiao, Cheng Guo, Guiqin Dai, Jie Lin, Deliang Liu, Man Rao, Zhiqiang Lin, Pengfei Zhao, Mingbin Zheng und 2 weitere

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1851410 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Lei Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, …. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections, Phage Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensively drug-resistant (XDR) Acinetobacter baumannii pneumonia carries severe pneumonia, respiratory failure and high mortality, showing limited therapeutic options in critically ill patients. Although bacteriophage (phage) therapy represents a promising alternative against drug-resistant infections, its clinical use remains largely empirical. Here, we reported a systematically planned phage-antibiotic combination strategy in a critically ill patient with refractory XDR A. baumannii pneumonia. A virulent phage targeting the patient-derived strain was isolated from hospital wastewater and classified within the class Caudoviricetes , with no virulence, toxin, or antibiotic resistance genes. In vitro time-kill assays showed that phage monotherapy failed to persistently suppress bacteria proliferation, whereas phage-antibiotic therapy achieved synergistic inhibition of A. baumannii growth for over 48 h. The patient received nebulized phage therapy (5 × 10 9 PFU/mL twice daily) combined with intravenous fosfomycin (8 g, every 8 hours), amikacin (0.2 g, every 12 hours), and polymyxin B (500, 000 U, every 12 hours). Clinically, treatment was associated with rapid normalization of arterial carbon dioxide tension (PaCO2), clearance of A. baumannii sputum cultures by day 4, declining inflammatory markers, and no treatment-related toxicity.Longitudinal metagenomic sequencing further revealed approximately 52-fold reduction in pathogen abundance and significant decrease of A. baumannii -associated antimicrobial resistance genes (ARGs) in the lung, highlighting the potential of precision phage-antibiotic therapy for recalcitrant XDR bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAnti-Bacterial AgentsAcinetobacter InfectionsPhage TherapyBacteriophagesPneumonia, BacterialHumansDrug Resistance, Multiple, BacterialFosfomycinPolymyxin BAmikacinMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Acinetobacter baumanniiantibioticsantimicrobial resistance genesbacteriophageextensive drug resistance

Substanzen

Anti-Bacterial AgentsFosfomycinPolymyxin BAmikacin

Autor:innen und Institutionen

  • National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.
  • School of Medicine, Shenzhen University, Shenzhen, China.
  • School of Public Health, Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Key Lab for Diagnosis & Treatment of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.
  • The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
  • Molecular Biology Research Center & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.

Zitieren

APA

Zhang, L., Yan, K., Xu, P., Xiao, Y., Guo, C., Dai, G., Lin, J., Liu, D., Rao, M., Lin, Z., Zhao, P., Zheng, M., Zhou, Y., & Lu, H. (2026). Phage-antibiotic synergy attenuates Acinetobacter baumannii resistance in refractory pneumonia: a precision therapeutic case. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1851410

Vancouver

Zhang L, Yan K, Xu P, Xiao Y, Guo C, Dai G, et al. Phage-antibiotic synergy attenuates Acinetobacter baumannii resistance in refractory pneumonia: a precision therapeutic case. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1851410

BibTeX
@article{Zhang2026,
  author = {Zhang, Lei and Yan, Kexin and Xu, Pengli and Xiao, Yanyu and Guo, Cheng and Dai, Guiqin and Lin, Jie and Liu, Deliang and Rao, Man and Lin, Zhiqiang and Zhao, Pengfei and Zheng, Mingbin and Zhou, Yang and Lu, Hongzhou},
  title = {Phage-antibiotic synergy attenuates Acinetobacter baumannii resistance in refractory pneumonia: a precision therapeutic case},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1851410}
}
Kostenlos starten →